451 related articles for article (PubMed ID: 28230454)
1. Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
Rascati KL; Worley K; Meah Y; Everhart D
J Manag Care Spec Pharm; 2017 Mar; 23(3):299-306. PubMed ID: 28230454
[TBL] [Abstract][Full Text] [Related]
2. Healthcare Costs Among Adults with Type 2 Diabetes Initiating DPP-4 Inhibitors.
Farr AM; Sheehan JJ; Brouillette M; Smith DM; Johnston SS; Kalsekar I
Adv Ther; 2016 Jan; 33(1):68-81. PubMed ID: 26724938
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
[TBL] [Abstract][Full Text] [Related]
4. Healthcare costs among adults with type 2 diabetes initiating saxagliptin or linagliptin: a US-based claims analysis.
Kong AM; Farahbakhshian S; Pendergraft T; Brouillette MA; Mukherjee B; Smith DM; Sheehan JJ
Curr Med Res Opin; 2017 Oct; 33(10):1869-1877. PubMed ID: 28613952
[TBL] [Abstract][Full Text] [Related]
5. Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease.
Huang H; Shetty S; Bauer E; Lang K
Curr Med Res Opin; 2018 Jun; 34(6):1021-1027. PubMed ID: 29231750
[TBL] [Abstract][Full Text] [Related]
6. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
Bergeson JG; Worley K; Louder A; Ward M; Graham J
J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
[TBL] [Abstract][Full Text] [Related]
7. Cost and clinical impact of a nonmedical DPP-4 inhibitor switch in patients with diabetes.
Kheloussi S; Johns A; Parente V; McLay W; Gionfriddo MR
J Manag Care Spec Pharm; 2021 Jul; 27(7):846-854. PubMed ID: 34185559
[No Abstract] [Full Text] [Related]
8. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Grabner M; Peng X; Geremakis C; Bae J
J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study.
Ofori-Asenso R; Ilomaki J; Chin KL; Mazidi M; Zomer E; Bell JS; Magliano DJ; Liew D
Diabetes Res Clin Pract; 2019 Dec; 158():107909. PubMed ID: 31697992
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Rapid-Acting Insulins in Adults with Diabetes.
Racsa PN; Meah Y; Ellis JJ; Saverno KR
J Manag Care Spec Pharm; 2017 Mar; 23(3):291-298. PubMed ID: 28230457
[TBL] [Abstract][Full Text] [Related]
11. Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis.
Gor D; Lee TA; Schumock GT; Walton SM; Gerber BS; Nutescu EA; Touchette DR
J Manag Care Spec Pharm; 2020 Jan; 26(1):67-75. PubMed ID: 31880221
[TBL] [Abstract][Full Text] [Related]
12. Does Hepatitis C Treatment Adherence Affect Risk of Liver Transplantation? A Historical Cohort Study.
Ems D; Racsa P; Anderson C; Gregory F; Worley K; Brill JV; Holt W
J Manag Care Spec Pharm; 2016 Jul; 22(7):863-71. PubMed ID: 27348286
[TBL] [Abstract][Full Text] [Related]
13. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China.
Lin WQ; Cai ZJ; Chen T; Liu MB; Li N; Zheng B
Front Endocrinol (Lausanne); 2021; 12():684960. PubMed ID: 34484112
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Nonadherence to Topical Intraocular Pressure Reduction Medications Among Medicare Members: A Claims-Based Retrospective Cohort Study.
Sheer R; Bunniran S; Uribe C; Fiscella RG; Patel VD; Chandwani HS
J Manag Care Spec Pharm; 2016 Jul; 22(7):808-817a. PubMed ID: 27348282
[TBL] [Abstract][Full Text] [Related]
16. Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.
Abbass IM; Caplan EO; Ng DB; Kristy R; Schermer CR; Bradt P; Collins JM; Chan WM; Suehs BT
J Manag Care Spec Pharm; 2017 Jan; 23(1):27-37. PubMed ID: 28025920
[TBL] [Abstract][Full Text] [Related]
17. Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting.
Chastek B; Korrer S; Nagar SP; Albers F; Yancey S; Ortega H; Forshag M; Dalal AA
J Manag Care Spec Pharm; 2016 Jul; 22(7):848-61. PubMed ID: 27348285
[TBL] [Abstract][Full Text] [Related]
18. Persistence with Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Effect on Clinical and Economic Outcomes: A Retrospective Claims Database Study.
Edelman SV; Ermakova A; Xiong Y; Sieradzan R; Taylor SD
J Manag Care Spec Pharm; 2019 Dec; 25(12):1420-1431. PubMed ID: 31550190
[TBL] [Abstract][Full Text] [Related]
19. Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder.
Ta JT; Sullivan SD; Tung A; Oliveri D; Gillard P; Devine B
J Manag Care Spec Pharm; 2021 Feb; 27(2):223-239. PubMed ID: 33506730
[No Abstract] [Full Text] [Related]
20. A Retrospective Database Study Comparing Diabetes-Related Medication Adherence and Health Outcomes for Mail-Order Versus Community Pharmacy.
Schwab P; Racsa P; Rascati K; Mourer M; Meah Y; Worley K
J Manag Care Spec Pharm; 2019 Mar; 25(3):332-340. PubMed ID: 30816817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
